DelMar Pharmaceuticals Inc  

(Public, OTCMKTS:DMPI)   Watch this stock  
Find more results for Jeffrey Garner
+0.06 (4.23%)
Nov 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.40 - 1.52
52 week 0.43 - 1.52
Open 1.43
Vol / Avg. 206,538.00/136,191.00
Mkt cap 55.14M
P/E     -
Div/yield     -
EPS -0.13
Shares 39.48M
Beta     -
Inst. own 0%
Nov 23, 2015
Q1 2016 DelMar Pharmaceuticals Inc Earnings Call
Nov 17, 2015
Q1 2016 DelMar Pharmaceuticals Inc Earnings Release
Nov 12, 2015
DelMar Pharmaceuticals Inc at SeeThruEquity LLC Microcap Investor Forum
Sep 9, 2015
DelMar Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 4, 2015
Full Year 2015 DelMar Pharmaceuticals Inc Earnings Call
Sep 4, 2015
Q4 2015 DelMar Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -231.98% -114.73%
Return on average equity - -
Employees 4 -
CDP Score - -


999 Broadway W Suite 720
+1-604-6295989 (Phone)

Website links


DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. Its drug candidate, VAL-083, is used in the United States as a treatment for glioblastoma multiforme (GBM). In addition to its clinical development activities in the United States, the Company has obtained certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its VAL-083 is granted orphan drug status by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The Company's product,VAL-083, represents a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.

Officers and directors

Jeffrey A. Bacha President, Chief Executive Officer, Director
Age: 47
Scott Praill Chief Financial Officer
Age: 49
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 65
William J. Garner M.D. Director
Age: 48
Robert J. Toth Jr Director
Age: 51
John K. Bell Independent Director
Age: 67
Lynda Sarah Cranston Independent Director
Age: 67
Erich Mohr Ph.D. Independent Director
Age: 60